Abstract
The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Dopaminergic Modulation of Sleep-Wake States
Volume: 16 Issue: 4
Author(s): Andrea Herrera-Solis, Wendy Herrera-Morales, Luis Nunez-Jaramillo and Oscar Arias-Carrion*
Affiliation:
- Unidad de Trastornos del Movimiento y Sueño (TMS). Hospital General Dr. Manuel Gea González, Avenida Calzada de Tlalpan 4800, Tlalpan, Sección XVI, Ciudad de México, C.P. 14080,Mexico
Keywords: Dopamine, dopamine agonist, sleep-wake states, wakefulness-promoting agents, receptors, nuclei.
Abstract: The role of dopamine in sleep-wake regulation is considered as a wakefulness-promoting agent. For the clinical treatment of excessive daytime sleepiness, drugs have been commonly used to increase dopamine release. However, sleep disorders or lack of sleep are related to several dopaminerelated disorders. The effects of dopaminergic agents, nevertheless, are mediated by two families of dopamine receptors, D1 and D2-like receptors; the first family increases adenylyl cyclase activity and the second inhibits adenylyl cyclase. For this reason, the dopaminergic agonist effects on sleep-wake cycle are complex. Here, we review the state-of-the-art and discuss the different effects of dopaminergic agonists in sleep-wake states, and propose that these receptors account for the affinity, although not the specificity, of several effects on the sleep-wake cycle.
Export Options
About this article
Cite this article as:
Herrera-Solis Andrea, Herrera-Morales Wendy , Nunez-Jaramillo Luis and Arias-Carrion Oscar *, Dopaminergic Modulation of Sleep-Wake States, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320145429
DOI https://dx.doi.org/10.2174/1871527316666170320145429 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimers Disease and Oxidative Stress: The Old Problem Remains Unsolved
Current Medicinal Chemistry - Central Nervous System Agents Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Drug Evolution: p-Aminobenzoic Acid as a Building Block
Current Medicinal Chemistry Pathways of T Cell Activation and Terminal Differentiation in Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Age-Related Decline in Melatonin and Its MT1 Receptor Are Associated with Decreased Sensitivity to Melatonin and Enhanced Mammary Tumor Growth
Current Aging Science Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Common and Distinct Interactions of Chemical Inhibitors with Cytochrome P450 CYP1A2, CYP2A6 and CYP2B6 Enzymes
Drug Metabolism Letters Paliperidone Use in the Elderly
Current Drug Safety Differences in Saccadic Eye Movements in Subjects at High and Low Risk for Panic Disorder
Current Pharmaceutical Design Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics Efficacy of Transcranial Direct Current Stimulation Combined with Cognitive Training in the Treatment of Apathy in Patients with Alzheimer’s Disease: Study Protocol for a Randomized Trial
Reviews on Recent Clinical Trials Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Clinical Drugs that Interact with St. Johns Wort and mplication in Drug Development
Current Pharmaceutical Design Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
CNS & Neurological Disorders - Drug Targets Effects of Melatonin on Ischemic Spinal Cord Injury Caused by Aortic Cross Clamping in Rabbits
Current Neurovascular Research Depressive Illness and Emotional Learning
Current Medical Imaging Network Analysis of Depressive Symptomatology in Elderly Patients with Major Depressive Disorder
Current Psychiatry Research and Reviews